Reviewing Bullfrog AI (NASDAQ:BFRG) & Ginkgo Bioworks (NYSE:DNA)
by Sarita Garza · The Markets DailyGinkgo Bioworks (NYSE:DNA – Get Free Report) and Bullfrog AI (NASDAQ:BFRG – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.
Institutional & Insider Ownership
78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 14.7% of Bullfrog AI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Ginkgo Bioworks and Bullfrog AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ginkgo Bioworks | -259.96% | -60.27% | -26.88% |
| Bullfrog AI | N/A | -150.36% | -127.98% |
Volatility and Risk
Ginkgo Bioworks has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of -2.73, indicating that its share price is 373% less volatile than the S&P 500.
Valuation and Earnings
This table compares Ginkgo Bioworks and Bullfrog AI”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ginkgo Bioworks | $170.15 million | 3.95 | -$312.76 million | ($5.01) | -1.99 |
| Bullfrog AI | $120,000.00 | 76.29 | -$6.50 million | ($0.46) | -1.07 |
Bullfrog AI has lower revenue, but higher earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Ginkgo Bioworks and Bullfrog AI, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ginkgo Bioworks | 2 | 2 | 0 | 0 | 1.50 |
| Bullfrog AI | 1 | 1 | 0 | 0 | 1.50 |
Ginkgo Bioworks currently has a consensus target price of $7.00, suggesting a potential downside of 29.82%. Given Ginkgo Bioworks’ higher possible upside, analysts clearly believe Ginkgo Bioworks is more favorable than Bullfrog AI.
Summary
Ginkgo Bioworks beats Bullfrog AI on 6 of the 11 factors compared between the two stocks.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.